While Cynvenio will still perform testing in its own lab right now, the firm's CEO said that interested labs could move the technology in house in the future if they desire.
The company also received a grant from the Maryland Innovation Initiative to help advance the device toward commercialization.
New data points to strong predictive ability for a ddPCR-based test of AR copy number, while other companies are pursuing tests that target expression of AR splice variants.
The company plans to submit a package to the FDA by the end of this year for use of the system in metastatic breast cancer patients, and then add other cancer types in the future.
The company's total revenues were $1.7 million, including $897,000 in commercial testing revenue. Its test volume was up 38 percent.
The company plans to use proceeds to advance its lead AR-V7 test with Genomic Health, accelerate other assays in its pipeline, and enhance its technology.
The firm's first assay will be for Hodgkin lymphoma, but a liquid biopsy test for prostate cancer has also shown strong predictive power in initial validation data.
At the AACR annual meeting earlier this month, attendees discussed challenges in demonstrating analytical and clinical validity appropriately for liquid biopsy tests.
At the AACR annual meeting last week researchers presented new data on a range of technologies, discussed novel platforms, compared existing tools, and explored new clinical uses.
The purchase from Janssen of a liquid biopsy test for circulating tumor cells marks Menarini-Silicon's entry into the US diagnostics market.
The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.
An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.
The US Department of Agriculture presents a new blueprint for animal genomic research.
In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.